Med Discovery SA - Product Pipeline Review - 2012

Date: July 16, 2012
Pages: 29
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M99C4481FDCEN
Leaflet:

Download PDF Leaflet

  • Abstracts
  • Contents
Med Discovery SA – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Med Discovery SA - Product Pipeline Review - 2012” provides data on the Med Discovery SA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Med Discovery SA’s corporate website, SEC filings, investor presentations and featured press releases, both from Med Discovery SA and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Med Discovery SA - Brief Med Discovery SA overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Med Discovery SA human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Med Discovery SA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Med Discovery SA’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Med Discovery SA’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Med Discovery SA in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Med Discovery SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Med Discovery SA.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Med Discovery SA and identify potential opportunities in those areas.
Keywords

Current R&D Portfolio of Med Discovery SA; Med Discovery SA - Key Therapeutics; Med Discovery SA - Pipeline Overview and Promising Molecules; Med Discovery SA - News; Med Discovery SA - Latest Updates; Med Discovery SA - Pipeline; Med Discovery SA - Discontinued/Dormant Projects
Med Discovery SA Snapshot
Med Discovery SA Overview
Key Information
Key Facts
Med Discovery SA – Research and Development Overview
Key Therapeutic Areas
Med Discovery SA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Med Discovery SA – Pipeline Products Glance
Med Discovery SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Med Discovery SA – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Med Discovery SA – Drug Profiles
MDAB16
Product Description
Mechanism of Action
R&D Progress
MDP01
Product Description
Mechanism of Action
R&D Progress
MDPK67b
Product Description
Mechanism of Action
R&D Progress
MDRG01
Product Description
Mechanism of Action
R&D Progress
Med Discovery SA – Pipeline Analysis
Med Discovery SA – Pipeline Products by Therapeutic Class
Med Discovery SA – Pipeline Products By Target
Med Discovery SA – Pipeline Products by Route of Administration
Med Discovery SA – Pipeline Products By Mechanism of Action
Med Discovery SA – Locations And Subsidiaries
Head Office
Med Discovery SA, Recent Developments
Med Discovery SA- Press Release
Nov 27, 2009: Orphan Drug Designation Of MDPK67b For Netherton Syndrome Approved
Jun 16, 2009: Med Discovery In-licenses Rasgap Chemotherapy Enhancer Technology
Financial Deals Landscape
Med Discovery SA, Deals Summary
Med Discovery SA, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Med Discovery Enters Into Research Agreement With DRAXIMAGE
Licensing Agreements
Med Discovery Enters Into Licensing Agreement With Dermadis For MDPK67b
Med Discovery Enters Into Licensing Agreement With University of Lausanne
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Med Discovery SA, Key Information
Med Discovery SA, Key Facts
Med Discovery SA – Pipeline by Indication, 2012
Med Discovery SA – Pipeline by Stage of Development, 2012
Med Discovery SA – Monotherapy Products in Pipeline, 2012
Med Discovery SA – Phase II, 2012
Med Discovery SA – Phase I, 2012
Med Discovery SA – Pre-Clinical, 2012
Med Discovery SA – Pipeline By Therapeutic Class, 2012
Med Discovery SA - Pipeline By Target, 2012
Med Discovery SA – Pipeline By Route of Administration, 2012
Med Discovery SA – Pipeline Products By Mechanism of Action, 2012
Med Discovery SA, Deals Summary
Med Discovery Enters Into Research Agreement With DRAXIMAGE
Med Discovery Enters Into Licensing Agreement With Dermadis For MDPK67b
Med Discovery Enters Into Licensing Agreement With University of Lausanne

LIST OF FIGURES

Med Discovery SA – Pipeline by Indication, 2012
Med Discovery SA – Pipeline by Stage of Development, 2012
Med Discovery SA – Monotherapy Products in Pipeline, 2012
Med Discovery SA – Pipeline By Therapeutic Class, 2012
Med Discovery SA - Pipeline By Target, 2012
Med Discovery SA - Pipeline Products By Mechanism of Action, 2012

Ask Your Question

Med Discovery SA - Product Pipeline Review - 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: